

Imatinib 3-years SSG XVIII

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Imatinib 3-years SSG XVIII

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival




Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Sarcoma
 Therapeutic Indication: Adjuvant for high-risk GIST patients with KIT-positive GIST removed at surgery
 Experimental Arm: Imatinib 3-years
 Control Arm: Imatinib 1-year

